Koers Bio-Path Holdings Inc Nasdaq
Aandelen
US09057N1028
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 4,16 mln. 3,88 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -11,18 mln. | Nettowinst (verlies) 2025 * | -13 mln. -12,11 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,14
x | K/w-verhouding 2025 * |
-0,14
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,89% |
Recentste transcriptie over Bio-Path Holdings Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | - | 10-05-07 | |
Peter Nielsen
CEO | Chief Executive Officer | 75 | 10-05-07 |
Douglas Morris
FOU | Founder | 68 | 10-05-07 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Douglas Morris
FOU | Founder | 68 | 10-05-07 |
Heath Cleaver
BRD | Director/Board Member | 51 | 11-02-14 |
Peter Nielsen
CEO | Chief Executive Officer | 75 | 10-05-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,28% | 48,09 mld. | |
-3,99% | 40,43 mld. | |
+45,32% | 40,62 mld. | |
-6,20% | 28,36 mld. | |
+6,36% | 24,89 mld. | |
-21,47% | 19,01 mld. | |
+27,58% | 12,09 mld. | |
-2,75% | 11,8 mld. | |
-2,02% | 11,88 mld. |